A Phase 1 interventional study of Tulisokibart Form 1 and Tulisokibart Form 2 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tulisokibart form 1.
Biological: Tulisokibart Form 1
Participants will receive tulisokibart form 2.
Biological: Tulisokibart Form 2
Solution for injection.
Also known as: MK-7240
Solution for injection.
Also known as: MK-7240
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart
Blood samples will be collected to determine the AUC0-inf of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart
Blood samples will be collected to determine the AUC0-last of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Maximum Plasma Concentration (Cmax) of Tulisokibart
Blood samples will be collected to determine the Cmax of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: At designated timepoints up to 14 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: At designated timepoints up to 14 weeks
Time to Maximum Plasma Concentration (Tmax) of Tulisokibart
Blood samples will be collected to determine the Tmax of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Apparent Clearance (CL/F) of Tulisokibart
Blood samples will be collected to determine the CL/F of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Apparent Volume of Distribution (V/F) of Tulisokibart
Blood samples will be collected to determine the V/F of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Apparent Terminal Half-life (t1/2) of Tulisokibart
Blood samples will be collected to determine the t1/2 of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Apparent Terminal Elimination Rate constant (Kel) of Tulisokibart
Blood samples will be collected to determine the Kel of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Ratio of AUC0-Last/AUC0-Inf of Tulisokibart
Blood samples will be collected to determine the ratio of AUC0-last/AUC0-inf of tulisokibart.
Time frame: At designated timepoints up to 14 weeks
Area Under the Concentration-Time Curve from Time 0 to Day 14 (pAUC0-14) of Tulisokibart
Blood samples will be collected to determine pAUC0-14 of tulisokibart.
Time frame: At designated timepoints up to 14 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2026 to primary completion in Sep 2026, 6 months.
Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tulisokibart